|
Medical News -
General Medical News - end 2009
|
|
Recent announcements by companies such as GlaxoSmithKline (GSK) and AstraZeneca state that they no longer intend to research new antidepressant drugs and ones to treat schizophrenia, leaving a black hole in the research pipeline. David Nutt, professor of neuropsychopharmacology at Imperial College London states: "What we have forgotten, and must not forget, is if we stop this research we will have a dead space of 20 to 30 years before we can re-tool again...
 Read more:
|
